For the Inventor, By the Inventor

Enter assignee name

Rensselaer, NY, United States of America

Nanopharmaceuticals LLC

Calculating rank

USPTO Granted Patents = 21

% Expired Patents = 42.9

CIPO Patents = 5

EPO Patents = 5

Forward Citations = 170

Loading Chart...

Loading Chart...

10 inventors (with patents filed for the assignee):

Shaker Ahmed Mousa (21 out of 81 patents)

Paul J Davis (13 out of 18 patents)

Faith B Davis (6 out of 11 patents)

4. Mehdi Rajabi (5 out of 5 patents)

5. Ozlem O Karakus (4 out of 4 patents)

6. Bruce Allan Hay (3 out of 27 patents)

7. Maria Alexander-Bridges (1 out of 1 patent)

8. Gennadi V Glinksy (1 out of 1 patent)

9. Aleck Hercbergs (1 out of 1 patent)

10. Hung-Yun Lin (1 out of 2 patents)

11. Gennadi V Glinsky (1 patent)

12. Shaker A Mousa (2 patents)

21 patents: Sort by Forward Citations

1. 11723888 - Polymer conjugated thyrointegrin antagonists (2023-08-15),

2. 11351137 - Composition and method for dual targeting in treatment of neuroendocrine tumors (2022-06-07),

3. 11186551 - Composition of scalable thyrointegrin antagonists with improved retention in tumors (2021-11-30),

4. 11077082 - Composition and method for dual targeting in treatment of neuroendocrine tumors (2021-08-03),

5. 10961204 - Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors (2021-03-30),

6. 10695436 - Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists (2020-06-30),

7. 10328043 - Composition and method for dual targeting in treatment of neuroendocrine tumors (2019-06-25),

8. 10201616 - Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists (2019-02-12),

9. 10130686 - Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders (2018-11-20),

10. 10060934 - Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof (2018-08-28),

11. 9980933 - Thyroid hormone analogs and methods of use (2018-05-29),

12. 9839614 - Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof (2017-12-12),

13. 9750709 - Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof (2017-09-05),

14. 9579300 - Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof (2017-02-28),

15. 9498536 - Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders (2016-11-22),

Company Overview

Nanopharmaceuticals LLC, based in Rensselaer, NY, specializes in the development and manufacturing of innovative pharmaceutical products utilizing nanotechnology. The company focuses on enhancing drug delivery systems to improve therapeutic efficacy and patient outcomes. By leveraging advanced research in nanomedicine, Nanopharmaceuticals aims to address complex medical challenges and contribute to the evolution of targeted therapies. Their expertise encompasses a range of applications within the pharmaceutical industry, emphasizing precision and effectiveness.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

21 Patents

#1 in Rensselaer, NY

#923 in New York

#15,719 in US

#30,018 in the World

Rensselaer, NY, United States of America

Nanopharmaceuticals LLC

Forward Citations = 170

10 inventors:

Shaker Ahmed Mousa (21 out of 81 patents)

Paul J Davis (13 out of 18 patents)

Faith B Davis (6 out of 11 patents)

4. Mehdi Rajabi (5 out of 5 patents)

5. Ozlem O Karakus (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nanopharmaceuticals LLC. Retrieved from https://idiyas.com/company/nanopharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…